Structured around developing a Leptin product as a hormone replacement therapy for Alzheimers disease, Neurotez Inc has used biochemistry, molecular & cell biology and in vivo models to identify potential biopharmaceuticals and utilized a novel screening procedure for protein candidates amenable to therapeutic manipulation. The firm's lead biopharmaceutical - Leptin - is \ an adipocyte hormone thought to be controling energy homeostasis, as a replacement therapy in elderly and Alzheimer's disease (AD) patients (patent pending). In addition, principals of the firm have identified a novel protein-protein interaction in a subset of familial cases of early onset AD. This abnormal interaction between mutated Presenilin with CLIP-170 is linked to higher Abeta levels, a small peptide believed to be the culprit of the disease pathology. Disruption of this interaction in vitro can lower Abeta production
